Neurogene Inc.
NGM: NGNELive Quote
📈 ZcoreAI Score
Our AI model analyzes Neurogene Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NGNE Z-Score →About Neurogene Inc.
Healthcare
Biotechnology
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
📊 Fundamental Analysis
Neurogene Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -31.4%, which indicates that capital utilization is currently under pressure.
At a current price of $20.38, NGNE currently sits at the 37th percentile of its 52-week range (Range: $10.28 - $37.27).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$317.40M
Trailing P/E
--
Forward P/E
-3.68
Beta (5Y)
1.89
52W High
$37.27
52W Low
$10.28
Avg Volume
158K
Day High
Day Low